newsfilter
← Latest News
Business Wire·

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela®